Is DAWN overvalued right now?
A stock is overvalued when its market price sits above a reasonable fair value range. Use the live snapshot on this page for DAWN, then validate with fundamentals and peer multiples.
Day One Biopharmaceuticals, Inc. (DAWN) is currently Undervalued by 6.50%
Instant valuation answer
Day One Biopharmaceuticals, Inc. (DAWN) appears undervalued by approximately 6.50% based on our live valuation percent and intrinsic value estimate derived from DCF, P/E Multiple, and P/S Multiple models. Valuation can still differ across analyst models, growth expectations, and risk assumptions.
- Upside (live) 6.50% (from live valuation API)
- Confidence (live) 4/10 (Low)
Confidence Score is based on the magnitude of upside or downside vs intrinsic value.
Fair value estimate
Unlock fair valueCurrent price
$21.53
Stock valuation checker
Search our company database (same as the site header). Choose a result or type a ticker and press Check valuation.
Explore Our Valuation Calculators
Why is Day One Biopharmaceuticals, Inc. overvalued or undervalued?
Intrinsic value work anchors Day One Biopharmaceuticals, Inc. on owner earnings and balance-sheet capacity; the current quote trades above that anchor, which frames the stock as relatively rich on a fundamentals-first view.
Versus historical valuation bands, DAWN is closer to the upper end of where this business has traded when profitability and growth were comparable—useful context before reading any single headline multiple.
Forward market expectations are elevated: the price requires heroic assumptions to converge with our fair-value zone, but sector peers and macro rates still deserve a quick sanity check on the company page.
Key metrics
- P/E ratio
- 9.1x
- Revenue growth (TTM y/y)
- 4%
- Profit margin
- 38.4%
- Fair value (model)
- Unlock
Frequently asked questions — DAWN
What is Day One Biopharmaceuticals, Inc.'s intrinsic value?
Our DCF, P/E Multiple, and P/S Multiple models estimate whether DAWN trades above or below fair value. At $21.53, Day One Biopharmaceuticals, Inc. currently looks undervalued on this snapshot. Tickerplace Pro unlocks the full dollar fair value estimate.
How is Day One Biopharmaceuticals, Inc.'s intrinsic value calculated?
Tickerplace calculates DAWN's fair value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We compare the resulting intrinsic value estimate to the live market price to flag undervalued or overvalued positioning.
Is DAWN undervalued right now?
Based on our 2026 valuation models, Day One Biopharmaceuticals, Inc. (DAWN) appears undervalued at $21.53 with about 6.5% upside to fair value. Treat this as a screen—verify fundamentals on the company profile.
Related companies — valuation
Peers for DAWN: open their overvalued / undervalued view.